{"brief_title": "Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer", "brief_summary": "The purpose of this study is to determine whether OSI-211 (Liposomal Lurtotecan) is an effective and safe treatment for patients with recurrent small cell lung cancer.", "condition": ["SCLC", "Carcinoma, Small Cell"], "intervention_type": ["Drug"], "intervention_name": ["OSI-211 (Liposomal Lurtotecan)"], "criteria": "Inclusion Criteria: - Confirmed recurrent small cell lung cancer. - One prior treatment of chemotherapy. - At least three weeks since last chemotherapy treatment and recovery from any related side effects. - At least three weeks since last chest radiotherapy and at least 10 days since head irradiation and recovery from acute side effects. - At least one target tumor less than or equal to 20 mm (or less than or equal to 10 mm on spiral CT-scan). - If a patient has had previous documented Central Nervous System (CNS) involvement, only controlled disease is acceptable. Exclusion Criteria: - Superior vena cava syndrome.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Small Cell Lung Cancer", "mesh_term": ["Lung Neoplasms", "Small Cell Lung Carcinoma", "Carcinoma, Small Cell", "Lurtotecan", "Camptothecin"], "id": "NCT00046787"}